Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inaticabtagene autoleucel - Juventas Cell Therapy/CASI Pharmaceuticals

Next Previous
Drug Profile

Inaticabtagene autoleucel - Juventas Cell Therapy/CASI Pharmaceuticals

Alternative Names: Anti-CD19 CAR-T cell therapy - Juventas Cell Therapy; CNCT-19; CNTC-19; HI19α-4-1BB-ζ CAR

Latest Information Update: 06 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chinese Academy of Medical Sciences
  • Developer CASI Pharmaceuticals; Juventas Cell Therapy
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor B-cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Registered Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Phase II Non-Hodgkin's lymphoma
  • Phase I/II Diffuse large B cell lymphoma
  • Phase I Autoimmune haemolytic anaemia; Idiopathic thrombocytopenic purpura
  • No development reported B-cell lymphoma

Most Recent Events

  • 27 Jul 2025 Juventas Cell Therapy plans a phase I trial for Autoimmune hemolytic anemia (Treatment-experienced) in July 2025 (NCT07091370)
  • 01 Mar 2025 Phase-I clinical trials in Idiopathic thrombocytopenic purpura (Treatment-experienced) in China (IV) (NCT06826430)
  • 14 Feb 2025 Juventas Cell Therapy plans to initiate a phase I trial for Autoimmune Thrombocytopenia (Second-line therapy or greater) (NCT06826430)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top